Ally Bridge Group Announces Key Promotions and New Appointment

Ally Bridge Group ("ABG"), a leading global healthcare investment firm focused on high-impact life science innovation, today announced several key promotions within its investment team and a new appointment to drive the firm's future growth and expansion as it celebrates its 10^th anniversary.

Key promotions include:

• Kevin Reilly to Managing Director, Head of Medtech for ABG's Private Equity strategy
• Andrew Lam, Pharm.D. to Managing Director, Head of Biotech for ABG's Private Equity strategy
• Slanix Paul Alex, Pharm.D. to Portfolio Manager and President for ABG's Public Equity strategy

New appointment:

• Zain Shekhani as Managing Director, Head of Investor Relations for ABG's Private Equity strategy

"We're excited to see Kevin, Andrew, and Slanix take on these leadership positions within our firm," said Frank Yu, Founder, Chief Executive Officer and Chief Investment Officer, Ally Bridge Group. "These promotions are well deserved. Kevin and Andrew have demonstrated a track record of successful investments and exits for ABG's Private Equity strategy amidst challenging market conditions. Slanix has successfully capitalized on investment opportunities against a volatile public market for ABG's Public Equity strategy since joining our team last year. I'm also thrilled to welcome Zain as our Head of Investor Relations for ABG's Private Equity strategy."

Ally Bridge Group, with a primary focus on U.S. investments, marks a significant milestone in its 10-year history with both private and public equity investment leads based in New York, alongside the core investment team. This alignment enhances our operational efficiency and underscores the firm's commitment to maximizing opportunities in life science investing.

Kevin Reilly, Managing Director, Head of Medtech for ABG's Private Equity strategy, joined the firm in 2021. Prior to joining ABG, Kevin served as a Principal at CRG, where he played a pivotal role in providing growth capital to healthcare companies through long-term debt and equity financing. Kevin began his career in healthcare investment banking at Stifel.

Andrew Lam, Pharm.D., Managing Director, Head of Biotech for ABG's Private Equity strategy, joined the firm in 2021. Prior to joining ABG, Andrew was Senior Director, Business Development at Intercept Pharmaceuticals and Vice President, Healthcare Investment Banking at Jefferies. A clinical pharmacist by training, Andrew brings more than two decades of experience in biotech.

Slanix Paul Alex, Pharm.D., Portfolio Manager and President for ABG's Public Equity strategy, joined the firm in January 2023. Prior to joining ABG, Slanix held leadership positions at public markets-focused healthcare investment managers, as a Founding Partner & Senior Analyst at Tri Locum Partners and Investment Analyst at Consonance Capital. A clinical pharmacist by training, Slanix brings additional experience in sell-side biotech equity research and life science strategy consulting.

Zain Shekhani joins as Managing Director, Head of Investor Relations for ABG's Private Equity strategy. Previously, he was a Managing Director at Leon Capital Group, overseeing capital formation and investor relations for private fund offerings and investments. Prior to that, Zain worked with Kevin Reilly at CRG, where he led capital formation and investor relations across various funds.

About Ally Bridge Group

Ally Bridge Group is a global healthcare investment firm focused on private and public high-impact life science innovation. Founded in 2013 by Frank Yu, the firm has led or co-led over $6 billion in healthcare transactions. The firm's mission is to generate superior risk-adjusted returns for investors guided by the core principle of selective investment in healthcare innovation that addresses unmet medical needs. Ally Bridge Group has offices in New York and Hong Kong. For more information, visit www.ally-bridge.com.

The information included in this press release is for informational purposes only and should not be construed as a solicitation or offer, or recommendation to acquire or dispose of any investment or to engage in any other transaction. If you would like investment, accounting, tax or legal advice, you should consult with your own financial advisors, accountants or attorneys regarding your individual circumstances and needs.